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Abstract
study on the redox biology of health and disease has come of age. Redox imbalance 
also defined as redox stress constitutes one of the main cellular lesion associated with 
many types of pathologies including cardiometabolic, neurodegenerative, oncologi-
cal, rheumatic and autoimmune diseases. Reactive species (either centered on oxygen 
or on nitrogen) can induce many damaging cellular processes, such as DNA oxidative 
lesions and loss of membrane integrity due to lipid peroxidation. Thus the evaluation 
of the redox imbalance of biological samples is extremely important in clinical prac-
tice as well as in research settings. This may constitute an important tool to evaluate 
the level of cellular lesions associated with specific pathological mechanisms, or the 
response to pharmacological and nonpharmacological treatment. The present review 
focuses on the molecular signatures of redox imbalance in various diseased processes. 
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introduction
The oxidative stress is the outcome 
of intense generation of reactive oxy-
gen species (ROS) and of reactive 
nitrogen species (RNS), which are 
not counteracted by endogenous an-
tioxidant molecules, therefore being 
the result of imbalance between the 
prooxidant and antioxidant systems. 
Currently, oxidative damage is linked 
to many types of pathologies includ-
ing cardiometabolic diseases (athero-
sclerosis, hypertension, obesity, type 
2 diabetes mellitus, and the metabolic 
syndrome), also neurodegenerative, 
cancer and rheumatic diseases (1,2). 
Free radicals are chemical species 
containing unpaired electrons, which 
are highly reactive and unstable, due 
to their structure; they can react lo-
cally, accepting or donating electrons, 
in order to become more stable. The 
reaction between a radical and a 
non-radical compound leads to the 
propagation of the radical chain reac-
tion, therefore generating a cascade of 
new free radicals. Many types of free 
radicals are generated during normal 
biochemical processes; among most 
reactive are the oxygen-, sulfur-, bro-
mide- and chloride-centered species 
(3). The most commonly reported cel-
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lular free radicals are centered on oxigen and are named ROS; 
among them most studied are singlet oxygen (1Σg+O2), hydroxyl 
(-OH), superoxide (O2
–) radicals. The free radicals centered on 
nitrogen are named reactive nitrogen species; most cited is the 
nitric monoxide (NO). Also, some other molecules, like hydro-
gen peroxide (H2O2) and peroxynitrite (ONOO
–) (which are not 
free radicals from the chemical point of view, having all-paired 
electrons) are reported to generate free radicals in living organ-
isms through various chemical reactions (3).
In order to counteract the damaging action of the physiologi-
cally generated ROS, the living organisms developed antioxidant 
systems. They act through different mechanisms: the transport of 
metal ions (e.g. iron, copper) by specific or non-specific proteins 
(ferritin, transferrin, albumin). Thus these ions can no longer 
participate in (i) redox reactions, (ii) arrest the ROS formation 
chain reaction, generally via antioxidants with small molecular 
mass, such as reduced glutathione (GSH), vitamins E and C, and 
uric acid, (iii) scavenging ROS with antioxidant enzymes such 
as superoxide dismutase (SOD), catalase (CAT), glutathione-
peroxidase (GPx), and glutathione-reductatse (GR), and (iv) the 
reparation of lesions caused by ROS via specific enzymes such as 
endonucleases, peroxidases, and lipases. 
The present review focuses on the molecular signatures of 
redox imbalance that can be used both in clinical and research 
practice.
Adipose-derived ros
Reactive species (ROS and RNS) can induce many damaging cel-
lular processes, such as DNA oxidative lesions, loss of membrane 
integrity due to lipid peroxidation and protein and carbohydrate 
structural changes. All these changes modify the normal meta-
bolic functions, thus resulting in pathological phenomena asso-
ciated with the increase of capillary permeability, impairment of 
the blood cell function and also the acceleration of aging process. 
ROS-induced damages are frequently associated with cancers 
(3,4), diabetes mellitus (5), rheumatoid arthritis (6,7), and obesity 
and related diseases (1,2,8-10). Of note, in obese mice, oxidative 
stress is enhanced in adipose tissue before diabetes development, 
suggesting that in obesity, adipose tissue may be a major source 
of ROS (1,8). Moreover, adipose-derived ROS is involved the de-
crease of circulating level of adiponectin, an essential event in the 
pathogenesis of metabolic syndrome and related disorders (8). Ac-
cordingly, treatment of obese mice with anti-oxidative agents im-
proves insulin resistance and restores adiponectin secretion (1,8).
redox status of biological samples 
Since the redox imbalance is associated with several patholo-
gies, the evaluation of the redox status of biological samples is 
extremely important in clinical practice as well as in research 
settings. Several methods for determining biomarkers of cellu-
lar oxidative stress have been developed, and some have been 
proposed for sensitive assessment of antioxidant defense and 
oxidative damage for example in diabetes and its complications 
(10-13).
The assessment of redox imbalance is focused on the type of 
cellular biomolecules that might be affected by the reactive spe-
cies - lipid peroxidation, protein modification, DNA oxidative 
changes. Generally, these processes do not occur individually – 
there is an overlap of the pathological changes induced by the 
redox imbalance. 
The term “biomarker” has been defined by The American Na-
tional Institute of Health as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacological responses 
to a therapeutic intervention”. Applications include diagnosis, 
prognosis and individualization of the therapy. The most prom-
ising biomarkers are the ones that closely correlate with the 
pathophysiological process of the disease (14-16).
The biochemical markers of the redox imbalance are difficult 
to classify. One criterion might be the type of molecules that are 
the target of the reactive species; depending on this, the mark-
ers might be specific for lipid peroxidation (malondialdehyde, 
hydroxy-trans-2-nonenal, thiobarbituric acid reactive substanc-
es - TBARS), isoprostanes, oxidized LDL particles), for protein 
oxidation (advances oxidation protein products – AOPP, protein 
carbonyls, nitrotyrosine), or for DNA oxidative damage (such as 
8-hydroxydeoxyguanosine-8-OHdG). 
Another very important issue is related to the specific func-
tion of the molecules that are assayed; for example, important 
markers of redox homeostasis are some important enzymes 
(such as catalase, superoxide dismutase, peroxidases, enzymes 
involved in the metabolism of glutathione – glutathione peroxi-
dase, glutathione reductase, DNA repair enzymes, etc). On the 
other hand, important molecules involved in the redox equilib-
rium are some vitamins – ascorbic acid, tocopherols, ubiqui-
nones, retinols, carotenes, or other small molecules (lipoic acid, 
uric acid, bilirubin) or proteins (albumin). Technically speaking, 
some assays show the global effect induced by increased reactive 
species production on biological samples ferric reducing ability 
of plasma (FRAP), oxygen radical absorbance capacity (ORAC), 
total antioxidant capacity (TAC). Enzymatic activities, on vita-
min assays or on genetic markers of oxidative stress are reviewed 
elsewhere (17,18). 
Markers of protein oxidation: AGe come of age
Studies show that radical-mediated oxidation of proteins leads 
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to fragmentation of the polypeptide chain, oxidation of amino 
acid side chains, and generation of protein–protein cross link-
ages. It was subsequently established that all of these protein 
modifications can also be mediated by metal-catalyzed oxida-
tion (MCO) systems. The attack of reactive species on protein 
generates carbonyl derivatives as markers of magnitude of pro-
tein oxidation; the carbonyl content of proteins has become the 
most generally used method for estimation of oxidative-stress-
mediated protein oxidation. Glycation and glycooxidation prod-
ucts also accumulate during exposure to oxidative stress (19).
The advanced glycation end products (AGE) formation pro-
cess, or the Maillard reaction, begins from Schiff bases and the 
Amadori product, a 1-amino-1-deoxyketose, produced by the 
reaction of the carbonyl group of a reducing sugar, like glucose, 
with proteins, lipids, and nucleic acid amino groups. During 
Amadori reorganization, these highly reactive intermediate car-
bonyl groups, known as α-dicarbonyls or oxoaldehydes, prod-
ucts of which include 3-deoxyglucosone and methylglyoxal, 
accumulate. Further glycation of proteins and lipids causes mo-
lecular rearrangements that lead to the generation of AGE. The 
α-dicarbonyls have the ability to react with amino, sulfhydryl, 
and guanidine functional groups in proteins. The reaction re-
sults in denaturation, browning, and cross-linking of the target-
ed proteins. In addition, the α-dicarbonyls can react with lysine 
and arginine functional groups on proteins, leading to the for-
mation of stable AGE compounds, such as Nε-(carboxymethyl)
lysine (CML), which are nonfluorescent AGE. Further, AGE 
form in vivo in hyperglycemic environments and during aging 
and contribute to the pathophysiology of cardiovascular disease 
in diabetes (20-23). Noteworthy, the research group of Hiroshi 
Yamamoto demonstrated that the expression of receptor for ad-
vanced glycation end products (RAGE) is found in adipocytes, 
immune cells, endothelial cells, and pancreatic β-cells, and im-
plicated RAGE in adipocyte hypertrophy and insulin resistance, 
thus in the development of obesity and type 2 diabetes (24, also 
see 14).
The plasma level of AGE can be evaluated using a fluorimet-
ric method, since AGE are fluorescent markers (25,26). Plasma 
samples are excited at 350 nm; the emission was registered be-
tween 350nm and 550nm, with the maximum at 450nm. 
Protein tyrosine nitration is mediated by reactive nitrogen 
species such as peroxynitrite (ONOO-) and nitrogen dioxide 
(NO2), and results in a nitro group adduct on susceptible tyros-
ine residues. Myeloperoxidase (MPO), with its transition metal 
centre, can react with ONOO- to yield oxo-metal complexes and 
NO2 thus facilitating the nitration reaction. Although the precise 
intermediates and mechanism for nitration in vivo have been a 
matter of controversy, measures of tyrosine nitration have been 
used as indicators of oxidative stress. Free nitrotyrosine can be 
measured by tandem mass spectrometry (MS/MS) coupled with 
GC or HPLC. Further studies are required to establish a normal 
basal range of circulating free nitrotyrosine in healthy individu-
als Other ways of quantifying protein nitration are immunocy-
tochemical and immu- nohistochemical assays based on either 
monoclonal or polyclonal nitrotyrosine antibodies. 
The carbonylation of protein represents the introduction of 
carbonyl groups (aldehyde or ketone) in the protein structure, 
through several mechanisms: by direct oxidation of the residues 
of lysine, arginine, proline and threonine residues from the pro-
tein chain, by interaction with lipid peroxidation products with 
aldehyde groups (such as 4-hydroxy-2-nonenal, malondialde-
hyde, 2-propenal), or by the interaction with the compounds 
with the carbonyl groups resulting from the degradation of 
the lipid or glycoxidation. All of these molecular changes oc-
cur under oxidative stress conditions. The protein carbonylation 
may constitute a marker for oxidative stress since it indicates in 
early stages and with accuracy the level of the oxidative damage. 
The assay of protein carbonyls may be based on spectrophoto-
metrical data (after derivatisation of the carbonyl groups with 
2,4-dinitrophenylhydrazine - DNPH), high-performance liquid 
chromatography (HLPC) method with diode-array detector (at 
370 nm) after an initial separation of the protein fractions by 
gel-filtration, gas chromatography (GC) or the immunoassay 
using specific antibodies (27-29). 
Markers of lipid peroxidation
Isoprostanes (IsoPs) are a family of stable, prostaglandin-like 
compounds gen- erated from the peroxidation of arachidonic 
acid, a polyunsaturated fatty acid present in phospholipids of 
cell membranes. The generation of IsoPs from arachidonic acid 
is independent of the cyclooxygenase enzyme that catalyzes the 
formation of prostaglandins from arachidonic acid. Isopros-
tanes are generated as a result of the action of ROS on mem-
brane lipids; the ROS may be generated from mitochondrial 
electron transport chain, P450, lipoxygenase or transition-metal 
catalyzed formation of free radicals. IsoPs are subsequently re-
leased from the cell membrane into circulation by phospholi-
pases, and can then be quantified in tissues, blood and urine. 
Most frequenly used methods for tha assay of IsoPs in plasma 
and urine samples are gas chromatography–mass spectrometry 
(GC/MS), liquid chromatography–mass spectrometry (LC/
MS), enzyme-linked immunosorbance assays (ELISA) and ra-
dioimmunoassay.
MDA is generated in vivo via peroxidation of polyunsaturat-
ed fatty acids. MDA interacts with proteins; for example MDA’s 
reaction with lysine residues generates lysine– lysine cross-links 
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which have been identified in apolipoproteinB (apoB) fractions 
of oxidized low density lipoprotein (OxLDL). MDA is typically 
quantified from plasma samples with the most popular method 
being a colorimetric assay based on the reaction between MDA 
and thiobarbituric acid (TBA). However, although suitable for 
high throughput analysis, this TBA reacting substances (TBARS) 
assay lacks specificity for MDA,with aldehydes other than MDA 
reacting with TBA to produce compounds that absorb in the 
same rangeas MDA. Several ELISA kits to detect MDA but also 
high-performance liquidc hromatography (HPLC) methods are 
available (16).
Monitoring the induced lipid peroxidation may also consti-
tute an important marker in the assessement of redox imbal-
ance, with great relevance on cardio-vascular risk evaluation. 
The susceptibility of lipoprotein particles to lipid peroxidation 
can be assessed, after the isolation of LDL, either by treatment 
with copper salts, with mixtures of ferric compounds and ascor-
bic acid, or other prooxidant systems. We previously published 
data regarding the assessment of induced lipid peroxidation 
markers in biological samples (30).
Global tests for the assay of redox status
The oxygen radical absorbance capacity (ORAC) assay measures 
the oxidative degradation of the fluorescent molecule (fluoresce-
in) after exposure to free radical generators ( azo-initiator com-
pounds, such as (2,2’-azobis-2-amidino-propane-dihydrochlo-
ride-AAPH). Antioxidants are considered to protect the fluores-
cent molecule from the oxidative degeneration. The fluorescent 
intensity decreases as the oxidative degeneration develops, and 
this intensity is typically recorded as time function after the ad-
dition of the free radical generator. The presence of the antioxi-
dant slows the fluorescence decay. Decay curves (fluorescence 
intensity vs. time) are recorded. Subsequently, the degree of 
antioxidant-mediated protection is quantified using the antioxi-
dant Trolox (a vitamin E analogue) as a standard. The method 
is especially used when measuring foods and supplements that 
contain complex ingredients with various slow- and fast-acting 
antioxidants, as well as ingredients with combined effects that 
cannot be pre-calculated.
The ferric reducing ability of plasma (FRAP) is a simple, au-
tomated test measuring the ferric reducing ability of plasma, and 
is used for assessing “antioxidant power.” Ferric to ferrous ion 
reduction at low pH causes a colored ferrous-tripyridyltriazine 
complex to form. FRAP values are obtained by comparing the 
absorbance change at 593 nm in test reaction mixtures with 
those containing ferrous ions in known concentration. Absorb-
ance changes are linear over a wide concentration range with 
antioxidant mixtures, including plasma, and with solutions con-
taining one antioxidant in purified form. There is no apparent 
interaction between antioxidants. The FRAP assay offers a pu-
tative index of antioxidant, or reducing, potential of biological 
fluids within the technological reach of every laboratory and 
researcher interested in oxidative stress and its effects (31).
Total antioxidant capacity, uses 2,2ʹ-azinobis-(3-ethylben-
zothia zoline-6-sulfonic acid radical cation (ABTS+), which is 
decolorized by antioxidants according to their concentrations 
and antioxidant capacities. This change in color is measured as 
a change in absorbance at 660 nm and the process is calibrated 
with Trolox. The assay has no interference from hemoglobin, 
bilirubin, EDTA or citrate (32).
Recent literature data mentions the use of fluorescent probes 
for the assessment of reactive species in biological samples, es-
pecially when speaking about non-specific processes. To deal 
with the issue of non-specificity to ROS species, newer probes 
that measure the nucleophilic nature of the superoxide anion 
rather than its oxidative properties have been developed. These 
probes incorporate leaving groups that when cleaved yield the 
free fluorescent molecule. In addition fluorophores such as ami-
nophenyl fluorescein and hydroxyphenyl fluorescein are more 
specific to downstream oxidants such as HOCl and the hydroxyl 
radical. AmplexRed is a highly sensitive fluorophore that specifi-
cally measures H2O2 (in picomolar range) in the presence of a 
catalyst (33).
Conclusion
Assessing the redox imbalances in biological samples may con-
stitute an important tool to evaluate the level of cellular lesions 
associated with specific pathological mechanisms, or the re-
sponse to pharmacological and nonpharmacological treatment. 
This may be important in “reading” of the redox signatures, par-
ticularly that “written” in the adipose tissue, as implicated in the 
pathogenesis and therapy of cardiometabolic diseases. Steps are 
yet to be made on this path of redox (patho)biology since most 
of the redox stress markers are not properly validated from the 
analytical point of view.
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